Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.

[1]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[2]  M. Ladanyi,et al.  Distinctive neoplasms characterised by specific chromosomal translocations comprise a significant proportion of paediatric renal cell carcinomas. , 2003, Pathology.

[3]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum , 2007, The American journal of surgical pathology.

[4]  K. Dykema,et al.  Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[5]  Holger Moch,et al.  Morphologic and Molecular Characterization of Renal Cell Carcinoma in Children and Young Adults , 2004, The American journal of surgical pathology.

[6]  S. Boorjian,et al.  The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. , 2008, European urology.

[7]  G. Kovacs,et al.  Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. , 1989, Journal of the National Cancer Institute.

[8]  R. Motzer,et al.  Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma , 2012, Cancer.

[9]  E. Plimack,et al.  Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy. , 2014, The Journal of urology.

[10]  P. Camparo,et al.  Hybrid oncocytic/chromophobe renal cell tumours do not display genomic features of chromophobe renal cell carcinomas , 2013, Virchows Archiv.

[11]  Ximing J. Yang,et al.  Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. , 2007, Cancer research.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[13]  S. Fleming,et al.  Collecting duct carcinoma of the kidney , 1986, Histopathology.

[14]  Lars Egevad,et al.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia , 2013, The American journal of surgical pathology.

[15]  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[16]  J. Cheville,et al.  Solid renal tumors: an analysis of pathological features related to tumor size. , 2003, The Journal of urology.

[17]  P. Russo,et al.  Chromophobe Renal Cell Carcinoma: A Clinicopathologic Study of 203 Tumors in 200 Patients With Primary Resection at a Single Institution , 2011, The American journal of surgical pathology.

[18]  C. Stief,et al.  Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. , 2013, The Journal of urology.

[19]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[20]  G. Alves,et al.  Pathology and Genetics , 2014 .

[21]  A. Belldegrun,et al.  Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance , 2011, BJU international.

[22]  R. Parker,et al.  Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy , 2005, Journal of immunotherapy.

[23]  J. Cheville,et al.  Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. , 2010, The Journal of urology.

[24]  B. Rini,et al.  Erratum: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial (Lancet (2011) 378 (1931-39)) , 2012 .

[25]  M. Ladanyi,et al.  Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation Service , 2013, The American journal of surgical pathology.

[26]  J. Cheville,et al.  Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[27]  P. Camparo,et al.  Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Z. Gatalica,et al.  Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases , 2010, Virchows Archiv.

[29]  A. Zisman,et al.  Renal oncocytoma--are there sufficient grounds to consider surveillance following prenephrectomy histologic diagnosis. , 2012, Urologic oncology.

[30]  T. Choueiri,et al.  Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.

[31]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Annals of Internal Medicine.

[32]  Arianna Di Napoli,et al.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.

[33]  M. Merino,et al.  The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome , 2007, The American journal of surgical pathology.

[34]  G. Demetri,et al.  Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors , 2012, Cancer.

[35]  J. Manola,et al.  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 , 2012, Medical Oncology.

[36]  S. Culine,et al.  Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.

[37]  Michael J Wallace,et al.  Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. , 2010, The Journal of urology.

[38]  R. Ghavamian,et al.  Renal medullary carcinoma: the Bronx experience. , 2007, Urology.

[39]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[40]  R. Uzzo,et al.  Pathological concordance and surgical outcomes of sporadic synchronous unilateral multifocal renal masses treated with partial nephrectomy. , 2013, The Journal of urology.

[41]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Scarpa,et al.  Pathology and Genetics , 2010 .

[43]  W Marston Linehan,et al.  The genetic basis of cancer of kidney cancer: implications for gene‐specific clinical management , 2005, BJU international.

[44]  W. Samlowski,et al.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Milowsky,et al.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.

[46]  R. Figlin,et al.  Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Mahul B. Amin,et al.  Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms: An Experience of 405 Cases , 2002, The American journal of surgical pathology.

[48]  A. G. Kessel,et al.  Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins , 2000, Oncogene.

[49]  R. Motzer,et al.  Medullary renal cell carcinoma and response to therapy with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Merino,et al.  Collecting duct carcinoma of the kidney. , 1990, Human pathology.

[51]  M. Atkins,et al.  Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. , 2009, Clinical genitourinary cancer.

[52]  L. Ngo,et al.  Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? , 2012, Radiology.

[53]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[54]  M. Colecchia,et al.  Treatment of collecting duct carcinoma: current status and future perspectives. , 2014, Anticancer research.

[55]  R. Grobholz,et al.  Collecting Duct Carcinomas Represent a Unique Tumor Entity Based on Genetic Alterations , 2013, PloS one.

[56]  B. Delahunt,et al.  Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. , 2002, Cancer research.

[57]  R. Motzer,et al.  Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  N. Vogelzang,et al.  Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era , 2013, PloS one.

[59]  Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 , 2009 .

[60]  P. Argani,et al.  Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. , 2013, Human pathology.

[61]  W. Linehan,et al.  Renal Tumors in the Birt-Hogg-Dubé Syndrome , 2002, The American journal of surgical pathology.

[62]  L. Schwartz,et al.  Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease , 2011, American journal of clinical oncology.

[63]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[64]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[65]  R. Motzer,et al.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  C. Lohse,et al.  Multifocal Renal Cell Carcinoma: Clinicopathologic Features and Outcomes for Tumors ≤4 cm , 2008, Advances in urology.

[67]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[68]  Amnon Zisman,et al.  Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[69]  B. Delahunt,et al.  Uncommon and recently described renal carcinomas , 2009, Modern Pathology.

[70]  J. Sosman,et al.  A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. , 2013 .

[71]  P. Choyke,et al.  Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. , 2007, The Journal of urology.

[72]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[73]  M. Remzi,et al.  Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC , 2008, BJU international.

[74]  W. Linehan,et al.  Targeting the mTOR pathway in Chromophobe Kidney Cancer , 2012, Journal of Cancer.

[75]  B. Delahunt,et al.  Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. , 2001, Human pathology.

[76]  W. Marston Linehan,et al.  Molecular Sub-Classification of Renal Epithelial Tumors Using Meta-Analysis of Gene Expression Microarrays , 2011, PloS one.

[77]  P. Russo,et al.  Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. , 2007, Journal of Urology.

[78]  L. Truong,et al.  Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms , 2005, Modern Pathology.

[79]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[80]  P. Argani,et al.  Translocation renal cell carcinoma , 2008, Cancer.

[81]  G. Kovacs,et al.  Molecular cytogenetics of renal cell tumors. , 1993, Advances in cancer research.

[82]  W. Rathmell,et al.  High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. , 2008, Urology.

[83]  A. Nagy,et al.  Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma , 2004, International journal of cancer.

[84]  Lisa L. Smith,et al.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.

[85]  F. Mostofi,et al.  Renal Medullary Carcinoma The Seventh Sickle Cell Nephropathy , 1995, The American journal of surgical pathology.

[86]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[87]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[88]  A. Belldegrun,et al.  Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? , 2009, The Journal of urology.

[89]  M. Gordon.  Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy , 2009 .

[90]  A. Belldegrun,et al.  Pathobiology and prognosis of chromophobe renal cell carcinoma. , 2008, Urologic oncology.

[91]  M. Zhou,et al.  Renal mass biopsy--a renaissance? , 2008, The Journal of urology.

[92]  Ximing J. Yang,et al.  Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma , 2010, BMC Cancer.

[93]  K. Moon,et al.  Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma , 2007, Journal of surgical oncology.

[94]  P. Tamboli,et al.  Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma , 2010, Cancer.

[95]  J. Srigley,et al.  Collecting duct carcinoma of kidney. , 1998, Seminars in diagnostic pathology.

[96]  B. Trock,et al.  Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. , 2012, Urology.

[97]  M. Ladanyi,et al.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.

[98]  S. Störkel,et al.  Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. , 1993, The American journal of pathology.

[99]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[100]  S. Störkel,et al.  Human chromophobe cell renal carcinoma , 1985, Virchows Archiv. B, Cell pathology including molecular pathology.

[101]  E. Jellinek.  Grawitz Tumor of Kidney. , 1904, California state journal of medicine.

[102]  R. Figlin,et al.  Collecting duct renal cell carcinoma: clinical study of a rare tumor. , 2002, The Journal of urology.

[103]  A. Belldegrun,et al.  Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma , 2012, BJU international.

[104]  N. Rioux-Leclercq,et al.  Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  M. Ladanyi,et al.  Translocation carcinomas of the kidney after chemotherapy in childhood. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  E. Perlman,et al.  Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. , 2002, Urology.

[107]  Y. Allory,et al.  Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  W. Linehan,et al.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. , 2012, The oncologist.

[109]  M. Ali,et al.  Sarcomatoid renal cell carcinoma: the chromophobe connection. , 1997, The American journal of surgical pathology.

[110]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[111]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[112]  L. Truong,et al.  Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma. , 2014, Human pathology.

[113]  R. Motzer,et al.  Treatment outcome for metastatic papillary renal cell carcinoma patients , 2006, Cancer.

[114]  Keith T Flaherty,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  D. Grignon,et al.  Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile , 2013, Modern Pathology.

[116]  Ximing J. Yang,et al.  Gene expression profiling of renal medullary carcinoma , 2004, Cancer.